Immune Repertoire Capture technology helps identify functional antibodies produced in patients during an immune response that have both utility themselves and can also be employed to identify the targets of an immune response. Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative.
The parties to the agreement in the first four years have decided to focus their attention on malaria, HIV/AIDS, and tuberculosis.Ītreca chief executive officer, chief scientific officer and co-founder Tito Serafini said, "This commitment from the foundation provides Atreca an opportunity to apply the Company’s Immune Repertoire CaptureTM technology to meet key challenges in global health." Atreca’s proprietary Immune Repertoire Capture® technology profiles a patient’s immune response at the single-cell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. Profiling of T- and B-cell receptor repertoires in an individual has led to a vast repository of information on acquired immunity against various microorganisms. Under the terms of the agreement, Atreca will apply the technology to particular infectious diseases and share the results with the foundation for use in the discovery and development of vaccines, therapeutics and diagnostics to be deployed in a defined group of countries.
0 kommentar(er)
